08:33 AM EDT, 06/07/2024 (MT Newswires) -- Plus Therapeutics ( PSTV ) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded in September 2022.

The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.

Additionally, Plus Therapeutics ( PSTV ) said it has named Greg Fuller vice president of medical affairs and medical director to oversee the commercial transition of the CNSide cerebrospinal fluid cancer diagnostic portfolio.

CNSide is expected to launch commercially by Q4, the company added.

Shares of the company were up more than 6% in recent Friday premarket activity.

Price: 2.6500, Change: +0.17, Percent Change: +6.85